Experimental Anesthetic Nidradine Blunts Pain Without Sedation
A 12,000-compound zebrafish screen produced a drug that puts mice under and dulls pain at doses that leave them awake. Every result so far is in animals.
The evidence is animal-only, and the study says so in plain terms.
A screen of 12,000 compounds in zebrafish larvae has produced nidradine, an experimental anesthetic that also dulls pain in mice at nonsedating doses.
The study, published in Nature Communications by Matthew McCarroll and co-authors, used automated cameras to track how larvae answered sound and light. Dozens of candidates survived the fish screen, and chemical refining narrowed the field to the single compound the team carried into mice.
The mouse results split from the standard drugs in two places. At doses that left mice coordinated on a rotating rod, nidradine cut heat-triggered pain behaviors while etomidate didn't, and at doses that removed the righting reflex it stopped withdrawal from a strong paw pinch that etomidate-treated mice still answered.
The safety contrast sits in the adrenal gland. Etomidate suppresses cortisol production, and nidradine didn't in the zebrafish tests or in tests on donated human adrenal tissue, a side effect that can turn severe in patients who are already critically ill.
Cell tests place the drug on a familiar target with a different grip. Nidradine boosts GABA-A receptor activity, and its binding site overlaps the sites propofol and etomidate use while sitting deeper toward the pore, and the authors say the pain effect may run through a different receptor they haven't identified.
The limits are the story's boundary, and they're wide. Every efficacy result comes from fish and mice, breathing effects and broader toxicity haven't been assessed, overall safety isn't established, and no human trial exists yet, so the emergency-care uses the authors sketch remain a research direction rather than a clinical option.
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.